It is noteworthy that both tumor types can focally express neuroendocrine markers (synaptophysin, chromogranin, and INSM1) in most SMARCA4-deficient carcinomas and up to 18% of SMARCB1-deficient carcinomas [61, 62]. This evidence concerns the gene SMARCA4 and neoplasm.